Four GLP-1 medications dominate the market: Ozempic, Wegovy, Mounjaro, and Zepbound. They're related but not identical — different active ingredients, different approved uses, different dosing schedules. This guide helps you understand the differences and have an informed conversation with your provider.
On this page
Quick comparison
| Feature | Ozempic | Wegovy | Mounjaro | Zepbound |
|---|---|---|---|---|
| Active ingredient | Semaglutide | Semaglutide | Tirzepatide | Tirzepatide |
| Manufacturer | Novo Nordisk | Novo Nordisk | Eli Lilly | Eli Lilly |
| FDA approval | Type 2 diabetes | Weight loss | Type 2 diabetes | Weight loss |
| Approval year | 2017 | 2021 | 2022 | 2023 |
| Max dose | 1.0 mg weekly | 2.4 mg weekly | 15 mg weekly | 15 mg weekly |
| Administration | Weekly injection | Weekly injection | Weekly injection | Weekly injection |
| Avg weight loss | 10-14% | 15% | 20-22% | 20-22% |
| Mechanism | GLP-1 only | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP |
Active ingredients explained
There are really only two active ingredients across these four medications:
Semaglutide (Ozempic, Wegovy)
A GLP-1 receptor agonist. Mimics the GLP-1 hormone to reduce appetite, slow gastric emptying, and improve insulin sensitivity. Approved for diabetes at lower doses (Ozempic) and weight loss at higher doses (Wegovy). Same drug, different brands and max doses.
Tirzepatide (Mounjaro, Zepbound)
A dual GIP/GLP-1 receptor agonist. Activates both the GLP-1 receptor AND the GIP receptor. The dual mechanism produces greater weight loss than GLP-1 alone. Approved for diabetes (Mounjaro) and weight loss (Zepbound). Same drug, different brands.
Effectiveness for weight loss
Clinical trial data on average weight loss at maximum dose:
- Ozempic (1.0mg): 10-14% weight loss (when used off-label for weight loss)
- Wegovy (2.4mg): 15% weight loss (FDA-approved for weight loss)
- Mounjaro (15mg): 20-22% weight loss (off-label for weight loss)
- Zepbound (15mg): 20-22% weight loss (FDA-approved for weight loss)
Tirzepatide (Mounjaro/Zepbound) is significantly more effective than semaglutide (Ozempic/Wegovy) for weight loss — about 5-7 percentage points more weight loss on average.
Side effect profiles
All four medications have similar side effect profiles (nausea, fatigue, constipation, etc.) because they share mechanisms. Differences:
- Tirzepatide (Mounjaro/Zepbound) tends to have slightly higher rates of nausea and GI side effects due to its dual mechanism and greater potency.
- Semaglutide (Ozempic/Wegovy) has a longer titration schedule, which spreads side effects over more time.
- Individual response varies — some users tolerate tirzepatide better than semaglutide, and vice versa.
For complete side effect information, see our side effects guide.
Cost and insurance coverage
Costs vary widely based on insurance coverage, manufacturer savings cards, and pharmacy. Approximate monthly costs without insurance:
- Ozempic: $800-950/month
- Wegovy: $1,200-1,400/month
- Mounjaro: $950-1,100/month
- Zepbound: $1,050-1,200/month
Insurance coverage varies:
- Diabetes diagnosis: Often covered (Ozempic, Mounjaro)
- Obesity diagnosis (BMI 30+) or overweight with comorbidity (BMI 27+): Often covered (Wegovy, Zepbound)
- Manufacturer savings cards: Can reduce out-of-pocket cost significantly, especially for commercially insured patients
Choosing the right one
Your provider will help you choose based on:
Medical considerations
- Type 2 diabetes diagnosis (favor Ozempic/Mounjaro)
- BMI and weight loss goals (favor Wegovy/Zepbound for higher weight loss)
- Cardiovascular disease (Wegovy has FDA approval for CV risk reduction)
- Other medical conditions and medications
Practical considerations
- Insurance coverage (often the deciding factor)
- Cost after insurance and savings cards
- Availability (some medications have had shortages)
- Personal preference for max weight loss vs. tolerability
Common scenarios
- Type 2 diabetes, modest weight loss needed: Ozempic
- Obesity, maximum weight loss: Zepbound (or Mounjaro off-label)
- Obesity with cardiovascular disease: Wegovy (FDA-approved for CV risk reduction)
- Needle aversion: Rybelsus (oral semaglutide, less effective but no injection)
- Insurance covers one but not others: Whichever is covered
This guide is informational only. Your healthcare provider is the best person to recommend which GLP-1 is right for you based on your medical history, current conditions, and treatment goals. Don't choose based on this guide alone.
FAQs
Is Mounjaro better than Wegovy?
For weight loss, yes — tirzepatide (Mounjaro/Zepbound) produces about 5-7 percentage points more weight loss than semaglutide (Wegovy). But individual response varies, and Wegovy may be preferable for users with cardiovascular disease or those who tolerate semaglutide better.
Can I switch from one GLP-1 to another?
Yes. Many users switch medications, often due to side effects, insurance changes, or effectiveness. See our switching guide for details. Switching should be done with provider supervision.
Are these medications safe long-term?
Current evidence supports long-term safety. GLP-1s have been used for diabetes management since 2005 (earlier generations) and 2017 (semaglutide). Long-term studies show sustained weight loss and metabolic benefits. Ongoing monitoring is recommended.
Will my insurance cover GLP-1 medication?
Varies widely. Most insurance plans cover at least one GLP-1 for diabetes. Coverage for weight loss (Wegovy, Zepbound) is less consistent and often requires documentation of BMI, comorbidities, or prior weight loss attempts. Manufacturer savings cards can help with out-of-pocket costs.
What about generic versions?
No generic GLP-1 medications are currently available in the US. Patents expire between 2031-2036, after which generics may become available. Compounded versions exist but quality varies — use only with provider supervision.
Related: Titration schedules · Switching medications · Side effects guide · Nutrition for Wegovy